𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Fas ligand expression in esophageal carcinomas and their lymph node metastases

✍ Scribed by Mamoun Younes; Mary R. Schwartz; Atilla Ertan; Delia Finnie; Anas Younes

Publisher
John Wiley and Sons
Year
2000
Tongue
English
Weight
178 KB
Volume
88
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

✦ Synopsis

BACKGROUND. Although esophageal adenocarcinomas (EADCA) have been shown

to have substantially reduced or absent Fas expression, the status of Fas ligand (FasL) in these tumors, especially adenocarcinomas, is largely unknown.

METHODS.

Using immunohistochemistry, the authors investigated FasL expression in sections of formalin fixed, paraffin embedded tissue from 13 EADCA. They also studied sections of 15 esophageal squamous cell carcinomas (ESCCA) and of lymph node metastases from 7 EADCA and 4 ESCCA. The percentage of FasL positive cells in each tumor was recorded. FasL expression in EADCA was compared with that in ESCCA and with lymph node status. Statistical analysis was performed using the Fisher exact test.

RESULTS.

No specific staining pattern was seen in adenocarcinomas. In ESCCA, FasL was often located in the cells at the periphery of tumor nests. All (100%) of EADCA showed FasL expression in greater than 25% of the cancer cells, and all were associated with lymph node metastasis. Fifty-three percent of ESCCA showed FasL expression in greater than 25% of the cancer cells and 33% had lymph node metastasis. Expression of FasL in greater than 25% of tumor cells was associated with a significantly higher incidence of lymph node metastasis (PΟ­0.0001). All lymph node metastases from esophageal carcinomas showed FasL immunoreactivity in greater than 50% of the metastatic tumor cells.

CONCLUSIONS.

FasL expression in greater than 25% of cancer cells correlates with a high incidence of lymph node metastasis in esophageal carcinomas. All cancer metastases in lymph nodes express FasL in ΟΎ50% of the cells. These findings indicate that FasL plays an important role in the immune evasion and metastasis of esophageal carcinomas.

πŸ“œ SIMILAR VOLUMES

Proliferative activity of esophageal car
Proliferative activity of esophageal carcinomas and their lymph node metastases: Comparison using argyrophilic nucleolar organizer region staining
✍ Yano, Koichi; Okamura, Takeshi; Yoshida, Yasunori; Ichiyoshi, Yuji; Yasumoto, Ko πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 69 KB πŸ‘ 1 views

Background: Many reports have concluded that quantification of the argyrophilic nucleolar organizer regions (AgNORs) measures proliferative activity and is a prognostic indicator in malignant disease. This retrospective study set out to evaluate the relationship between the AgNORs of the primary tum

The number of lymph node metastases infl
The number of lymph node metastases influences survival in esophageal cancer
✍ Kawahara, Katsunobu; Maekawa, Takahumi; Okabayashi, Kan; Shiraishi, Takeshi; Yos πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 27 KB πŸ‘ 1 views

Background and Objectives: Lymph node involvement adversely affects the survival of patients with esophageal cancer. We retrospectively investigated whether the number of involved lymph nodes and the degree of lymph node dissection affect survival. Patients and Methods: Eighty-eight patients underwe

Expression of bcl-2 protein in esophagea
Expression of bcl-2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis
✍ Makoto Ohbu; Makoto Saegusa; Nobuyuki Kobayashi; Hideto Tsukamoto; Hironobu Mien πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 188 KB πŸ‘ 2 views

## Background: Recent studies on the role of bcl-2 in malignant tumors have suggested its prognostic significance. the goals of the current study were to determine any correlation between bcl-2 expression in esophageal squamous cell carcinoma and histopathology, lymph node metastasis, and clinical